US5585362A
(en)
*
|
1989-08-22 |
1996-12-17 |
The Regents Of The University Of Michigan |
Adenovirus vectors for gene therapy
|
AU680459B2
(en)
*
|
1992-12-03 |
1997-07-31 |
Genzyme Corporation |
Gene therapy for cystic fibrosis
|
WO1994023582A1
(en)
*
|
1993-04-08 |
1994-10-27 |
Genetic Therapy, Inc. |
Adenoviral vectors including dna encoding lung surfactant protein
|
FR2705686B1
(fr)
|
1993-05-28 |
1995-08-18 |
Transgene Sa |
Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
|
US6133028A
(en)
*
|
1993-05-28 |
2000-10-17 |
Transgene S.A. |
Defective adenoviruses and corresponding complementation lines
|
WO1994029471A1
(en)
|
1993-06-10 |
1994-12-22 |
Genetic Therapy, Inc. |
Adenoviral vectors for treatment of hemophilia
|
US20020136708A1
(en)
|
1993-06-24 |
2002-09-26 |
Graham Frank L. |
System for production of helper dependent adenovirus vectors based on use of endonucleases
|
SK282843B6
(sk)
*
|
1993-07-13 |
2002-12-03 |
Rhone-Poulenc Rorer S. A. |
Defektný rekombinantný adenovírus a farmaceutický prostriedok s jeho obsahom
|
US5631236A
(en)
*
|
1993-08-26 |
1997-05-20 |
Baylor College Of Medicine |
Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
|
US6057299A
(en)
*
|
1994-01-13 |
2000-05-02 |
Calydon, Inc. |
Tissue-specific enhancer active in prostate
|
US5830686A
(en)
*
|
1994-01-13 |
1998-11-03 |
Calydon |
Tissue-specific enhancer active in prostate
|
US5698443A
(en)
*
|
1995-06-27 |
1997-12-16 |
Calydon, Inc. |
Tissue specific viral vectors
|
DE69533295T3
(de)
*
|
1994-02-16 |
2009-07-16 |
The Government Of The United States Of America, As Represented By The Secretary, The Department Of Health And Human Services |
Melanoma-assoziierte Antigene, Epitope davon und Impstoffe gegen Melanoma
|
US7252989B1
(en)
*
|
1994-04-04 |
2007-08-07 |
Board Of Regents, The University Of Texas System |
Adenovirus supervector system
|
JPH10507061A
(ja)
*
|
1994-04-28 |
1998-07-14 |
ザ ユニバーシティ オブ ミシガン |
アデノウイルス中にパッケージされたプラスミドdnaを用いる遺伝子送達ベクターおよびパッケージング細胞株
|
US6451571B1
(en)
|
1994-05-02 |
2002-09-17 |
University Of Washington |
Thymidine kinase mutants
|
DE69535178T2
(de)
*
|
1994-06-10 |
2006-12-14 |
Genvec, Inc. |
Adenoviren-vektor systeme und zelllinien
|
US5851806A
(en)
*
|
1994-06-10 |
1998-12-22 |
Genvec, Inc. |
Complementary adenoviral systems and cell lines
|
EP0707071B1
(de)
*
|
1994-08-16 |
2003-07-30 |
Crucell Holland B.V. |
Von Adenovirus abgeleitete rekombinante Vektoren, für Gentherapie
|
FR2725213B1
(fr)
*
|
1994-10-04 |
1996-11-08 |
Rhone Poulenc Rorer Sa |
Vecteurs viraux et utilisation en therapie genique
|
FR2725726B1
(fr)
*
|
1994-10-17 |
1997-01-03 |
Centre Nat Rech Scient |
Vecteurs viraux et utilisation en therapie genique
|
DK0787200T3
(da)
*
|
1994-10-28 |
2005-08-15 |
Univ Pennsylvania |
Forbedret adenovirus og fremgangsmåder til anvendelse heraf
|
FR2726285B1
(fr)
*
|
1994-10-28 |
1996-11-29 |
Centre Nat Rech Scient |
Adenovirus depourvus de particules contaminantes viables, preparation et utilisation
|
US5872005A
(en)
*
|
1994-11-03 |
1999-02-16 |
Cell Genesys Inc. |
Packaging cell lines for adeno-associated viral vectors
|
AU709498B2
(en)
*
|
1994-12-12 |
1999-09-02 |
Genetic Therapy, Inc. |
Improved adenoviral vectors and producer cells
|
FR2729674B1
(fr)
*
|
1995-01-20 |
1997-04-11 |
Centre Nat Rech Scient |
Cellules pour la production d'adenovirus recombinants
|
IL116816A
(en)
*
|
1995-01-20 |
2003-05-29 |
Rhone Poulenc Rorer Sa |
Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
|
FR2738575B1
(fr)
*
|
1995-09-08 |
1997-10-10 |
Centre Nat Rech Scient |
Cellules pour la production d'adenovirus recombinants
|
FR2741891B1
(fr)
*
|
1995-06-01 |
1998-01-09 |
Centre Nat Rech Scient |
Cellules pour la production d'adenovirus recombinants
|
FR2730411B1
(fr)
*
|
1995-02-14 |
1997-03-28 |
Centre Nat Rech Scient |
Association medicamenteuse utile pour la transfection et l'expression in vivo d'exogenes
|
US6372208B1
(en)
|
1999-09-28 |
2002-04-16 |
The Trustees Of The University Of Pennsylvania |
Method of reducing an immune response to a recombinant virus
|
US6251957B1
(en)
|
1995-02-24 |
2001-06-26 |
Trustees Of The University Of Pennsylvania |
Method of reducing an immune response to a recombinant virus
|
FR2731710B1
(fr)
*
|
1995-03-14 |
1997-04-30 |
Rhone Poulenc Rorer Sa |
Virus recombinants exprimant la lecithine cholesterol acyltransferase et utilisations en therapie genique
|
JP3770333B2
(ja)
*
|
1995-03-15 |
2006-04-26 |
大日本住友製薬株式会社 |
組換えdnaウイルスおよびその製造方法
|
US5707618A
(en)
*
|
1995-03-24 |
1998-01-13 |
Genzyme Corporation |
Adenovirus vectors for gene therapy
|
FR2732357B1
(fr)
|
1995-03-31 |
1997-04-30 |
Rhone Poulenc Rorer Sa |
Vecteurs viraux et utilisation pour le traitement des desordres hyperproliferatifs, notamment de la restenose
|
CA2218610A1
(en)
*
|
1995-04-17 |
1996-10-24 |
Board Of Regents, The University Of Texas System |
An adenovirus helper-virus system
|
US6281010B1
(en)
|
1995-06-05 |
2001-08-28 |
The Trustees Of The University Of Pennsylvania |
Adenovirus gene therapy vehicle and cell line
|
US5698202A
(en)
*
|
1995-06-05 |
1997-12-16 |
The Wistar Institute Of Anatomy & Biology |
Replication-defective adenovirus human type 5 recombinant as a rabies vaccine carrier
|
US5756283A
(en)
*
|
1995-06-05 |
1998-05-26 |
The Trustees Of The University Of Pennsylvania |
Method for improved production of recombinant adeno-associated viruses for gene therapy
|
US6019978A
(en)
*
|
1995-06-05 |
2000-02-01 |
The Wistar Institute Of Anatomy And Biology |
Replication-defective adenovirus human type 5 recombinant as a vaccine carrier
|
US5985846A
(en)
*
|
1995-06-07 |
1999-11-16 |
Baylor College Of Medicine |
Gene therapy for muscular dystrophy
|
ES2333425T5
(es)
*
|
1995-06-15 |
2012-08-28 |
Crucell Holland B.V. |
Sistemas de empaquetado para adenovirus recombinante humano destinados a terapia génica
|
US6265212B1
(en)
|
1995-06-15 |
2001-07-24 |
Introgene B.V. |
Packaging systems for human recombinant adenovirus to be used in gene therapy
|
US6783980B2
(en)
*
|
1995-06-15 |
2004-08-31 |
Crucell Holland B.V. |
Packaging systems for human recombinant adenovirus to be used in gene therapy
|
FR2735789B1
(fr)
*
|
1995-06-23 |
1997-07-25 |
Centre Nat Rech Scient |
Adenovirus recombinants, leur utilisation pour preparer des aav, lignee cellulaire complementaire et compositions pharmaceutiques les contenant
|
US6676935B2
(en)
|
1995-06-27 |
2004-01-13 |
Cell Genesys, Inc. |
Tissue specific adenoviral vectors
|
US7163925B1
(en)
|
1995-07-17 |
2007-01-16 |
Board Of Regents, The University Of Texas System |
p16 expression constructs and their application in cancer therapy
|
HUP9901908A3
(en)
|
1995-07-17 |
2000-02-28 |
Univ Texas |
P16 expression constructs and their application in cancer therapy
|
FR2737221B1
(fr)
*
|
1995-07-24 |
1997-10-17 |
Transgene Sa |
Nouveaux vecteurs viraux pour la therapie genique
|
FR2737222B1
(fr)
*
|
1995-07-24 |
1997-10-17 |
Transgene Sa |
Nouveaux vecteurs viraux et lignee pour la therapie genique
|
WO1997005266A1
(en)
*
|
1995-07-25 |
1997-02-13 |
Introgene B.V. |
Methods and means for targeted gene delivery
|
US5837511A
(en)
*
|
1995-10-02 |
1998-11-17 |
Cornell Research Foundation, Inc. |
Non-group C adenoviral vectors
|
US6004797A
(en)
*
|
1995-11-09 |
1999-12-21 |
Avigen, Inc. |
Adenovirus helper-free recombinant AAV Virion production
|
JP2006075171A
(ja)
*
|
1995-11-09 |
2006-03-23 |
Avigen Inc |
組換えaavビリオン産生における使用のための補助機能
|
CA2177085C
(en)
*
|
1996-04-26 |
2007-08-14 |
National Research Council Of Canada |
Adenovirus e1-complementing cell lines
|
WO1997045550A2
(en)
*
|
1996-05-31 |
1997-12-04 |
Baxter International Inc. |
Mini-adenoviral vector
|
IL127692A0
(en)
*
|
1996-07-01 |
1999-10-28 |
Rhone Poulenc Rorer Sa |
Method for producing recombinant adenovirus
|
FR2750433B1
(fr)
*
|
1996-07-01 |
1998-08-14 |
Rhone Poulenc Rorer Sa |
Procede de production d'adenovirus recombinants
|
US20040156861A1
(en)
|
1996-07-11 |
2004-08-12 |
Figdor Carl Gustav |
Melanoma associated peptide analogues and vaccines against melanoma
|
US6544523B1
(en)
|
1996-11-13 |
2003-04-08 |
Chiron Corporation |
Mutant forms of Fas ligand and uses thereof
|
CZ299055B6
(cs)
|
1996-12-06 |
2008-04-09 |
Aventis Pharmaceuticals Inc. |
Izolovaný polypeptid kódovaný genem podobným genupro lipázu, prostredek mající fosfolipázovou úcinnost, farmaceutický prostredek, izolovaný imunizacní peptid a nukleová kyselina, biologicky aktivní prostredek, vektor, rekombinantní bunka, prostredek
|
US7008776B1
(en)
*
|
1996-12-06 |
2006-03-07 |
Aventis Pharmaceuticals Inc. |
Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol
|
US6403370B1
(en)
|
1997-02-10 |
2002-06-11 |
Genstar Therapeutics Corporation |
Oncolytic/immunogenic complementary-adenoviral vector system
|
WO1998037185A2
(en)
*
|
1997-02-20 |
1998-08-27 |
The Board Of Regents Of The University Of Texas System |
Vectors for controlled gene expression
|
FR2761689B1
(fr)
|
1997-04-02 |
1999-06-25 |
Transgene Sa |
Fibre adenovirale modifiee et adenovirus cibles
|
US6638502B1
(en)
|
1997-04-28 |
2003-10-28 |
Gencell Sas |
Adenovirus-mediated intratumoral delivery of an angiogenesis antagonist for the treatment of tumors
|
US5849561A
(en)
*
|
1997-05-22 |
1998-12-15 |
Cornell Research Foundation, Inc. |
Method for the production of non-group C adenoviral vectors
|
WO1998054345A1
(en)
*
|
1997-05-30 |
1998-12-03 |
Baxter International Inc. |
Mini-adenoviral vector
|
FR2766091A1
(fr)
|
1997-07-18 |
1999-01-22 |
Transgene Sa |
Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee
|
US6696423B1
(en)
|
1997-08-29 |
2004-02-24 |
Biogen, Inc. |
Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
|
JP4303418B2
(ja)
*
|
1997-10-24 |
2009-07-29 |
ライフ テクノロジーズ コーポレーション |
組換え部位を有する核酸を使用する組換えクローニング
|
US6653088B1
(en)
|
1997-10-24 |
2003-11-25 |
Aventis Pharma S.A. |
Interaction test for the investigation of inhibitory molecules of the interaction between a presenilin and the β-amyloid peptide
|
CA2308606A1
(en)
|
1997-11-06 |
1999-05-20 |
Chiron S.P.A. |
Neisserial antigens
|
DE69926729T2
(de)
|
1998-01-08 |
2006-06-08 |
Aventis Pharmaceuticals Inc. |
Transgenes kaninchen, dass ein funktionelles menschliches lipoprotein(a) exprimiert
|
AU1979599A
(en)
|
1998-01-14 |
1999-08-02 |
Chiron S.P.A. |
(neisseria meningitidis) antigens
|
DE69933856D1
(de)
|
1998-02-13 |
2006-12-14 |
Koester Hubert |
Verwendung von ribozymen zur bestimmung der funktion von genen
|
US5981225A
(en)
*
|
1998-04-16 |
1999-11-09 |
Baylor College Of Medicine |
Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
|
US6670188B1
(en)
|
1998-04-24 |
2003-12-30 |
Crucell Holland B.V. |
Packaging systems for human recombinant adenovirus to be used in gene therapy
|
BR9910089A
(pt)
|
1998-05-01 |
2004-06-08 |
Chiron Corp |
Composições e antìgenos de neisseria meningitidis
|
US6225456B1
(en)
|
1998-05-07 |
2001-05-01 |
University Technololy Corporation |
Ras suppressor SUR-5
|
US6506889B1
(en)
|
1998-05-19 |
2003-01-14 |
University Technology Corporation |
Ras suppressor SUR-8 and related compositions and methods
|
US6413776B1
(en)
|
1998-06-12 |
2002-07-02 |
Galapagos Geonomics N.V. |
High throughput screening of gene function using adenoviral libraries for functional genomics applications
|
CN1342206A
(zh)
|
1998-08-28 |
2002-03-27 |
杜克大学 |
在IVa2,100K和/或preterminal protein序列上有缺失的腺病毒
|
US6225113B1
(en)
|
1998-12-04 |
2001-05-01 |
Genvec, Inc. |
Use of trans-activation and cis-activation to modulate the persistence of expression of a transgene in an at least E4-deficient adenovirus
|
DE19856065A1
(de)
*
|
1998-12-04 |
2000-06-15 |
Centeon Pharma Gmbh |
Rekombinanter, adenoviraler Vektor mit limitierter Autoreplikationsfähigkeit in vivo
|
FR2787465A1
(fr)
*
|
1998-12-21 |
2000-06-23 |
Transgene Sa |
Procede d'inactivation des virus enveloppes dans une preparation virale de virus non enveloppes
|
EP1016726A1
(de)
*
|
1998-12-30 |
2000-07-05 |
Introgene B.V. |
Gentherapie zur Förderung der Angiogenesis
|
US6441156B1
(en)
*
|
1998-12-30 |
2002-08-27 |
The United States Of America As Represented By The Department Of Health And Human Services |
Calcium channel compositions and methods of use thereof
|
JP2004501602A
(ja)
*
|
1999-02-18 |
2004-01-22 |
メルク アンド カンパニー インコーポレイテッド |
エンドヌクレアーゼの使用に基づくヘルパー依存アデノウイルスベクターの生産のためのシステム
|
ES2162551B1
(es)
*
|
1999-04-09 |
2002-07-01 |
Univ Madrid Autonoma |
Procedimiento para la replicacion selectiva de adenovirus defectivos en celulas tumorales.
|
US6490775B1
(en)
*
|
1999-04-23 |
2002-12-10 |
Veri-Tek Inc. |
Press operation verification system
|
RU2245366C2
(ru)
|
1999-04-30 |
2005-01-27 |
Чирон С.Р.Л. |
Антиген neisseria, кодирующая его нуклеиновая кислота, их использование
|
US7226786B2
(en)
|
1999-05-18 |
2007-06-05 |
Dnavec Research Inc. |
Envelope gene-deficient Paramyxovirus vector
|
US20030166252A1
(en)
*
|
1999-05-18 |
2003-09-04 |
Kaio Kitazato |
Paramyxovirus-derived RNP
|
GB9911683D0
(en)
|
1999-05-19 |
1999-07-21 |
Chiron Spa |
Antigenic peptides
|
FR2794771B1
(fr)
*
|
1999-06-11 |
2001-08-10 |
Aventis Pharma Sa |
Adenovirus recombinants codant pour le transporteur specifique de l'iode (nis)
|
EP1200622A4
(de)
*
|
1999-07-06 |
2004-12-22 |
Merck & Co Inc |
Hiv impfstoff aus einem das gag-gen tragenden adenovirus
|
GB9916529D0
(en)
|
1999-07-14 |
1999-09-15 |
Chiron Spa |
Antigenic peptides
|
FR2799472B1
(fr)
*
|
1999-10-07 |
2004-07-16 |
Aventis Pharma Sa |
Preparation d'adenovirus recombinants et de banques adenovirales
|
EP2275552B1
(de)
|
1999-10-29 |
2015-09-09 |
GlaxoSmithKline Biologicals SA |
Antigenpeptide aius Neisseria
|
CN1254719A
(zh)
*
|
1999-11-19 |
2000-05-31 |
钱其军 |
一种缺陷型腺病毒及其构建方法
|
US6558948B1
(en)
|
1999-11-23 |
2003-05-06 |
Stefan Kochanek |
Permanent amniocytic cell line, its production and use for the production of gene transfer vectors
|
PT2289545T
(pt)
|
2000-01-17 |
2016-09-06 |
Glaxosmithkline Biologicals Sa |
Vacina de omv suplementada contra meningococos
|
ATE486089T1
(de)
|
2000-03-31 |
2010-11-15 |
Aventis Pharma Inc |
Nuklearfaktor kb induzierender faktor
|
GB0018307D0
(en)
|
2000-07-26 |
2000-09-13 |
Aventis Pharm Prod Inc |
Polypeptides
|
US20040204379A1
(en)
*
|
2000-06-19 |
2004-10-14 |
Cheng Seng H. |
Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
|
EP1167533A1
(de)
*
|
2000-06-23 |
2002-01-02 |
Vereniging Voor Christelijk Wetenschappelijk Onderwijs |
Verfahren und Mittel zur Komplementation von viraler Proteinexpression in stabilen Zelllinien
|
US7198924B2
(en)
|
2000-12-11 |
2007-04-03 |
Invitrogen Corporation |
Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
|
US6733993B2
(en)
*
|
2000-09-15 |
2004-05-11 |
Merck & Co., Inc. |
Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
|
US20040101957A1
(en)
*
|
2001-09-14 |
2004-05-27 |
Emini Emilio A. |
Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol.nef and modifications
|
AU9456201A
(en)
*
|
2000-09-15 |
2002-03-26 |
Merck & Co Inc |
Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications
|
US6916635B2
(en)
*
|
2000-10-02 |
2005-07-12 |
The Research Foundation Of State University Of New York |
Hybrid adenovirus/adeno-associated virus vectors and methods of use thereof
|
MXPA03003690A
(es)
|
2000-10-27 |
2004-05-05 |
Chiron Spa |
Acidos nucleicos y proteinas de los grupos a y b de estreptococos.
|
US7060442B2
(en)
|
2000-10-30 |
2006-06-13 |
Regents Of The University Of Michigan |
Modulators on Nod2 signaling
|
JP2002142770A
(ja)
*
|
2000-11-08 |
2002-05-21 |
Dnavec Research Inc |
循環系への遺伝子送達用パラミクソウイルスベクター
|
ES2359625T3
(es)
|
2000-12-28 |
2011-05-25 |
Wyeth Llc |
Proteina protectora recombinante de.
|
GB0107661D0
(en)
|
2001-03-27 |
2001-05-16 |
Chiron Spa |
Staphylococcus aureus
|
GB0107658D0
(en)
|
2001-03-27 |
2001-05-16 |
Chiron Spa |
Streptococcus pneumoniae
|
AUPR518501A0
(en)
|
2001-05-22 |
2001-06-14 |
Unisearch Limited |
Yin yang-1
|
US6682929B2
(en)
|
2001-07-23 |
2004-01-27 |
Genvec, Inc. |
Adenovector complementing cells
|
US6677156B2
(en)
|
2001-07-23 |
2004-01-13 |
Genvec, Inc. |
Non-adenoviral gene product-based complementing cells for adenoviral vectors
|
MX339524B
(es)
|
2001-10-11 |
2016-05-30 |
Wyeth Corp |
Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
|
ES2312649T3
(es)
|
2001-12-12 |
2009-03-01 |
Novartis Vaccines And Diagnostics S.R.L. |
Inmunizacion frente a chlamydia trachomatis.
|
US20030158112A1
(en)
|
2002-02-15 |
2003-08-21 |
Johns Hopkins University School Of Medicine |
Selective induction of apoptosis to treat ocular disease
|
ES2310247T3
(es)
*
|
2002-04-25 |
2009-01-01 |
Crucell Holland B.V. |
Vectores adenovirales estables y metodos de propagacion de los mismos.
|
CN100358581C
(zh)
*
|
2002-04-30 |
2008-01-02 |
株式会社载体研究所 |
具有降低的血凝活性的药物载体组合物或基因载体组合物
|
US7217796B2
(en)
|
2002-05-24 |
2007-05-15 |
Schering Corporation |
Neutralizing human anti-IGFR antibody
|
WO2004009768A2
(en)
*
|
2002-07-18 |
2004-01-29 |
Invitrogen Corporation |
Viral vectors containing recombination sites
|
CA2421269A1
(en)
|
2002-08-09 |
2004-02-09 |
President And Fellows Of Harvard College |
Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
|
US7977049B2
(en)
|
2002-08-09 |
2011-07-12 |
President And Fellows Of Harvard College |
Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
|
US7785608B2
(en)
|
2002-08-30 |
2010-08-31 |
Wyeth Holdings Corporation |
Immunogenic compositions for the prevention and treatment of meningococcal disease
|
US20040052161A1
(en)
*
|
2002-09-17 |
2004-03-18 |
Steven Liao |
Mechanical clock having wireless manipulation and adjustment function
|
US20060104950A1
(en)
*
|
2002-10-24 |
2006-05-18 |
Shinji Okano |
Methods of Tranducing genes into T cells
|
EP1563074B1
(de)
|
2002-11-12 |
2018-01-10 |
VAXum, LLC. |
Adenovirusvektor-impfstoff
|
AU2003300076C1
(en)
|
2002-12-30 |
2010-03-04 |
Angiotech International Ag |
Drug delivery from rapid gelling polymer composition
|
GB0308198D0
(en)
|
2003-04-09 |
2003-05-14 |
Chiron Srl |
ADP-ribosylating bacterial toxin
|
ATE459707T1
(de)
*
|
2003-06-30 |
2010-03-15 |
Dnavec Research Inc |
Negativ-strang rna-virus-vektoren, welche ein gen mit veränderten hypermutierbaren regionen tragen
|
BRPI0412279A
(pt)
*
|
2003-07-02 |
2006-09-19 |
Diversa Corp |
glucanases, ácidos nucléicos codificando as mesmas e métodos para preparar e aplicar os mesmos
|
US7026164B2
(en)
*
|
2003-07-03 |
2006-04-11 |
Cell Genesys, Inc. |
Adenovirus packaging cell lines
|
CA2532783C
(en)
|
2003-07-21 |
2013-09-17 |
Transgene S.A. |
Polypeptide having an improved cytosine deaminase activity
|
AU2004263274B2
(en)
|
2003-07-21 |
2009-11-05 |
Transgene S.A. |
Novel multifunctional cytokines
|
US8299229B2
(en)
|
2003-11-24 |
2012-10-30 |
Microvax, Llc |
Mucin antigen vaccine
|
EP1697534B1
(de)
*
|
2003-12-01 |
2010-06-02 |
Life Technologies Corporation |
Rekombinationsstellen enthaltende nukleinsäuremoleküle und verfahren zur verwendung davon
|
US8828957B2
(en)
*
|
2003-12-11 |
2014-09-09 |
Microvax, Llc |
Methods for generating immunity to antigen
|
WO2005058369A2
(en)
*
|
2003-12-15 |
2005-06-30 |
The University Of Iowa Research Foundation |
Compositions of l-caldesmon for treating viral infection
|
KR20070004637A
(ko)
*
|
2004-01-22 |
2007-01-09 |
가부시키가이샤 디나벡크 겐큐쇼 |
바이러스 벡터의 제조방법
|
US7432057B2
(en)
|
2004-01-30 |
2008-10-07 |
Michigan State University |
Genetic test for PSE-susceptible turkeys
|
AU2005214090B2
(en)
*
|
2004-02-23 |
2008-09-11 |
Crucell Holland B.V. |
Virus purification methods
|
PT1736541E
(pt)
|
2004-03-29 |
2013-01-31 |
Galpharma Co Ltd |
Nova proteína galectina 9 modificada e sua utilização
|
JP2007532656A
(ja)
|
2004-04-12 |
2007-11-15 |
アメリカ合衆国 |
アデノウイルスベクターを用いて免疫応答を誘導するための方法
|
US7604798B2
(en)
|
2004-07-15 |
2009-10-20 |
Northwestern University |
Methods and compositions for importing nucleic acids into cell nuclei
|
WO2006020071A2
(en)
|
2004-07-16 |
2006-02-23 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Vaccines against aids comprising cmv/r-nucleic acid constructs
|
US20080126007A1
(en)
*
|
2004-08-04 |
2008-05-29 |
S.A.E. Afikim Computerized Dairy Management System |
Method and a System for Locating Objects in a Defined Area
|
JP2008536479A
(ja)
|
2005-02-11 |
2008-09-11 |
ユニバーシティ オブ サザン カリフォルニア |
ジスルフィド架橋を有するタンパク質の発現法
|
CN101155915B
(zh)
*
|
2005-04-11 |
2013-12-04 |
克鲁塞尔荷兰公司 |
利用超滤进行病毒纯化
|
DK2002003T3
(en)
|
2005-05-27 |
2016-03-21 |
Ospedale San Raffaele Srl |
Gene vector comprising miRNA
|
US20060286074A1
(en)
*
|
2005-05-31 |
2006-12-21 |
Yucheng Tang |
Methods for immunotherapy of cancer
|
JP2009505680A
(ja)
|
2005-08-31 |
2009-02-12 |
ジェンベク、インコーポレイティッド |
アデノウイルスベクターに基づくマラリアワクチン
|
WO2007030588A1
(en)
*
|
2005-09-07 |
2007-03-15 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Use of replicators to prevent gene silencing
|
KR20080068098A
(ko)
|
2005-10-28 |
2008-07-22 |
디나벡크 가부시키가이샤 |
Rna 바이러스 또는 dna 바이러스의 스파이크단백질로 슈도타입화된 렌티바이러스 벡터를 사용한 기도상피 간세포로의 유전자 도입
|
US9533036B2
(en)
*
|
2005-11-07 |
2017-01-03 |
Microvax, Llc |
Methods for generating immune responses to influenza antigens with a secretable CD40L fusion protein
|
EP1951297A2
(de)
|
2005-11-10 |
2008-08-06 |
GenVec, Inc. |
Adenoviraler vektorbasierter impfstoff für die maul- und klauen-seuche
|
US8008256B2
(en)
*
|
2006-05-01 |
2011-08-30 |
University Of Southern California |
Combination therapy for treatment of cancer
|
US20110206692A1
(en)
|
2006-06-09 |
2011-08-25 |
Novartis Ag |
Conformers of bacterial adhesins
|
BRPI0714981A2
(pt)
|
2006-07-28 |
2013-08-13 |
Sanofi Aventis |
composiÇço, mÉtodo para fazer a mesma a qual compreende um inibidor que inibe a atividade de uma proteÍna do complexo iii, um veÍculo e um membro da superfamÍlia da fator de necrose de tumor, mÉtodo para conduzir um ensaio para determinar se um composto É um inibidor de atividade de supressço de tnf de uma proteÍna do complexo iii e uso de um composto
|
JP5238710B2
(ja)
|
2006-10-19 |
2013-07-17 |
シーエスエル、リミテッド |
インターロイキン−13レセプターアルファ1の高親和性抗体アンタゴニスト
|
US8613925B2
(en)
|
2006-10-19 |
2013-12-24 |
Csl Limited |
Anti-IL-13Rα1 antibodies and their uses thereof
|
AR064642A1
(es)
|
2006-12-22 |
2009-04-15 |
Wyeth Corp |
Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
|
CN101617052A
(zh)
|
2007-01-30 |
2009-12-30 |
特兰斯吉恩股份有限公司 |
用于免疫的乳头瘤病毒e2多肽
|
US8470977B2
(en)
|
2008-03-14 |
2013-06-25 |
Transgene S.A. |
Antibody against the CSF-1R
|
ES2337973B8
(es)
|
2008-05-16 |
2011-07-21 |
Proyecto De Biomedicina Cima, S.L. |
Adenovirus auxiliares auto-inactivantes para la produccion de adenovirus recombinantes de alta capacidad.
|
ES2532015T3
(es)
*
|
2008-11-03 |
2015-03-23 |
Crucell Holland B.V. |
Método para la producción de vectores adenovíricos
|
AU2009313615B2
(en)
|
2008-11-05 |
2012-11-29 |
Regents Of The University Of Minnesota |
Multicomponent immunogenic composition for the prevention of beta-hemolytic streptococcal (BHS) disease
|
WO2010056901A2
(en)
|
2008-11-13 |
2010-05-20 |
University Of Southern California |
Method of expressing proteins with disulfide bridges with enhanced yields and activity
|
BRPI1006179A2
(pt)
|
2009-01-13 |
2016-02-23 |
Transgène S A |
uso de uma fração de ácidos nucleicos mitocondriais, composição adjuvante, composição de vacina, e, kit da parte
|
ES2536747T3
(es)
|
2009-01-20 |
2015-05-28 |
Transgene Sa |
ICAM 1 soluble como biomarcador para predicción de respuesta terapéutica
|
WO2010096561A1
(en)
|
2009-02-18 |
2010-08-26 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Synthetic hiv/siv gag proteins and uses thereof
|
NZ595290A
(en)
|
2009-03-24 |
2012-09-28 |
Transgene Sa |
Biomarker for monitoring patients
|
RU2555340C2
(ru)
|
2009-04-17 |
2015-07-10 |
Трансжене Са |
Биомаркер для мониторинга пациентов
|
JP5650212B2
(ja)
|
2009-07-10 |
2015-01-07 |
トランジェーヌ、ソシエテ、アノニムTransgene S.A. |
患者を選択するためのバイオマーカーおよび関連方法
|
SG178254A1
(en)
|
2009-08-07 |
2012-03-29 |
Transgene Sa |
Composition for treating hbv infection
|
AU2010305765B2
(en)
|
2009-10-15 |
2015-07-02 |
Crucell Holland B.V. |
Method for the purification of adenovirus particles
|
CN102575233B
(zh)
|
2009-10-15 |
2014-07-16 |
克鲁塞尔荷兰公司 |
从高细胞密度培养物纯化腺病毒的方法
|
WO2011047316A1
(en)
|
2009-10-16 |
2011-04-21 |
The United States Of America, As Represented By The Secretary Department Of Health And Human Services |
Nucleic acid sequences encoding expandable hiv mosaic proteins
|
WO2011057254A2
(en)
|
2009-11-09 |
2011-05-12 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Simian adenoviral vector-based vaccines
|
JP5980117B2
(ja)
|
2009-11-09 |
2016-08-31 |
ジェンヴェック,インコーポレーテッド |
サルアデノウイルスベクターの増殖方法
|
WO2011098592A1
(en)
|
2010-02-15 |
2011-08-18 |
Crucell Holland B.V. |
Method for the production of ad26 adenoviral vectors
|
ES2887335T3
(es)
|
2010-03-17 |
2021-12-22 |
Univ Cornell |
Vacuna contra las drogas de abuso basada en adenovirus alterado
|
WO2012021730A2
(en)
|
2010-08-11 |
2012-02-16 |
Genvec, Inc. |
Respiratory syncytial virus (rsv) vaccine
|
ES2850973T3
(es)
|
2010-08-23 |
2021-09-01 |
Wyeth Llc |
Formulaciones estables de antígenos rLP2086 de Neisseria meningitidis
|
WO2012032489A1
(en)
|
2010-09-10 |
2012-03-15 |
Wyeth Llc |
Non-lipidated variants of neisseria meningitidis orf2086 antigens
|
US8771709B2
(en)
|
2010-09-20 |
2014-07-08 |
Crucell Holland B.V. |
Therapeutic vaccination against active Tuberculosis
|
US9168292B2
(en)
|
2010-09-27 |
2015-10-27 |
Crucell Holland B.V. |
Heterologous prime boost vaccination regimen against malaria
|
WO2012083297A2
(en)
|
2010-12-17 |
2012-06-21 |
Genvec, Inc. |
Adenoviral vectors with modified hexon regions
|
WO2012088041A1
(en)
|
2010-12-20 |
2012-06-28 |
Genvec, Inc. |
Adenoviral vector-based dengue fever vaccine
|
CN103403159B
(zh)
|
2011-02-08 |
2018-09-14 |
国立大学法人三重大学 |
用于基因导入的病毒载体的制造方法
|
EP2708600A4
(de)
|
2011-04-28 |
2015-01-07 |
Univ Yamaguchi |
Umkehrungs-primer mit einer beendigungssequenz für überexpression und lineare dns
|
WO2012162428A1
(en)
|
2011-05-23 |
2012-11-29 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Prime-boost vaccination for viral infection
|
TWI575070B
(zh)
|
2011-07-12 |
2017-03-21 |
傳斯堅公司 |
Hbv聚合酶突變體
|
WO2013045668A2
(en)
|
2011-09-29 |
2013-04-04 |
Transgene Sa |
Immunotherapy composition and regimen for treating hepatitis c virus infection
|
TW201318637A
(zh)
|
2011-09-29 |
2013-05-16 |
Transgene Sa |
免疫療法組成物及用於治療c型肝炎病毒感染之療程(一)
|
US9233153B2
(en)
|
2011-10-05 |
2016-01-12 |
Genvec, Inc. |
Affenadenovirus (gorilla) or adenoviral vectors and methods of use
|
BR112014008249B1
(pt)
|
2011-10-05 |
2022-03-15 |
Genvec Inc |
Adenovírus ou vetor adenoviral e composição com os mesmos
|
EP2764011B1
(de)
|
2011-10-05 |
2021-04-07 |
GenVec, Inc. |
Auf adenovirenvektoren-basierender impfstoff gegen das respiratorische synzytialvirus (rsv)
|
BR112014008284A2
(pt)
|
2011-10-05 |
2020-10-27 |
Genvec Inc. |
adenovirus (gorilla) simian ou vetores adenovirais e métodos de uso
|
EP2780034A1
(de)
|
2011-11-14 |
2014-09-24 |
Crucell Holland B.V. |
Heterologe prime-boost-impfung mit auf masernviren basierten impfstoffen
|
US20150157700A1
(en)
|
2012-02-02 |
2015-06-11 |
GanVec, Inc. |
Adenoviral vector-based malaria vaccine
|
NZ628449A
(en)
|
2012-03-09 |
2016-04-29 |
Pfizer |
Neisseria meningitidis compositions and methods thereof
|
SA115360586B1
(ar)
|
2012-03-09 |
2017-04-12 |
فايزر انك |
تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
|
CN104379733B
(zh)
|
2012-03-12 |
2016-01-20 |
克鲁塞尔荷兰公司 |
具改变末端的重组腺病毒群
|
US8932607B2
(en)
|
2012-03-12 |
2015-01-13 |
Crucell Holland B.V. |
Batches of recombinant adenovirus with altered terminal ends
|
MY169352A
(en)
|
2012-03-22 |
2019-03-25 |
Janssen Vaccines & Prevention Bv |
Vaccine against rsv
|
US9125870B2
(en)
|
2012-03-22 |
2015-09-08 |
Crucell Holland B.V. |
Vaccine against RSV
|
EP2855669B1
(de)
|
2012-05-29 |
2018-10-10 |
GenVec, Inc. |
Modifizierte serotyp-28-adenovirusvektoren
|
US9676824B2
(en)
|
2012-05-29 |
2017-06-13 |
Genvec, Inc. |
Herpes simplex virus vaccine
|
WO2014009433A1
(en)
|
2012-07-10 |
2014-01-16 |
Transgene Sa |
Mycobacterium resuscitation promoting factor for use as adjuvant
|
JP6333814B2
(ja)
|
2012-07-10 |
2018-05-30 |
トランジェーヌ、ソシエテ、アノニムTransgene S.A. |
マイコバクテリア抗原ワクチン
|
US9657076B2
(en)
|
2012-10-23 |
2017-05-23 |
Emory University |
GM-CSF and IL-4 conjugates, compositions, and methods related thereto
|
WO2014107739A1
(en)
|
2013-01-07 |
2014-07-10 |
Eleven Biotherapeutics, Inc. |
Antibodies against pcsk9
|
JP6446377B2
(ja)
|
2013-03-08 |
2018-12-26 |
ファイザー・インク |
免疫原性融合ポリペプチド
|
CA2940513C
(en)
|
2013-03-11 |
2023-08-15 |
University Of Florida Research Foundation, Inc. |
Delivery of card protein as therapy for ocular inflammation
|
MX361774B
(es)
|
2013-04-25 |
2018-12-17 |
Janssen Vaccines & Prevention Bv |
Polipéptidos f de prefusión del virus sincicial respiratorio (rsv) solubles y estabilizados.
|
PE20160045A1
(es)
|
2013-06-17 |
2016-02-18 |
Crucell Holland Bv |
Polipeptidos f de prefusion del virus sincicial respiratorio (rsv) solubles y estabilizados
|
CA2923129C
(en)
|
2013-09-08 |
2020-06-09 |
Pfizer Inc. |
Neisseria meningitidis compositions and methods thereof
|
PL3046536T3
(pl)
|
2013-09-19 |
2019-06-28 |
Janssen Vaccines & Prevention B.V. |
Ulepszone formulacje adenowirusów
|
JP6605480B2
(ja)
|
2014-01-09 |
2019-11-13 |
トランスジェン・ソシエテ・アノニム |
ヘテロオリゴマーマイコバクテリア抗原の融合物
|
EP3107939B1
(de)
|
2014-02-19 |
2020-06-17 |
University of Florida Research Foundation, Inc. |
Abgabe einer nrf2-therapie zum schutz gegen reaktive sauerstoffspezies
|
WO2016037154A1
(en)
|
2014-09-04 |
2016-03-10 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Recombinant hiv-1 envelope proteins and their use
|
CN107075521B
(zh)
|
2014-11-04 |
2021-06-08 |
扬森疫苗与预防公司 |
治疗性hpv16疫苗
|
EP3236998A1
(de)
|
2014-12-24 |
2017-11-01 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Rekombinante metapneumovirusproteine und deren verwendung
|
JP7020917B2
(ja)
|
2015-01-20 |
2022-02-16 |
ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
キメラrsv/bpiv3 fタンパクを発現する組換えヒト/ウシパラインフルエンザウイルス3(b/hpiv3)およびその使用
|
BR112017017460A2
(pt)
|
2015-02-19 |
2018-04-10 |
Pfizer Inc. |
composições de neisseria meningitidis e métodos das mesmas
|
WO2016131945A1
(en)
|
2015-02-20 |
2016-08-25 |
Transgene Sa |
Combination product with autophagy modulator
|
EP3261665A1
(de)
|
2015-02-24 |
2018-01-03 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Mers-coronavirusimmunogene, antikörper und deren verwendung
|
DK3271729T3
(da)
|
2015-03-18 |
2020-12-14 |
Janssen Vaccines & Prevention Bv |
Analyser til rekombinante ekspressionssystemer
|
JP6960396B2
(ja)
|
2015-04-07 |
2021-11-05 |
ザ ジェイ. デビッド グラッドストーン インスティテューツ、 ア テスタメンタリー トラスト エスタブリッシュド アンダー ザ ウィル オブ ジェイ. デビッド グラッドストーン |
分裂終了細胞の細胞分裂を誘発するための方法
|
US10570417B2
(en)
|
2015-04-14 |
2020-02-25 |
Janssen Vaccines & Prevention B.V. |
Recombinant adenovirus expressing two transgenes with a bidirectional promoter
|
JP6840718B2
(ja)
|
2015-07-07 |
2021-03-10 |
ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. |
安定化された可溶性融合前rsv fポリペプチド
|
WO2017005844A1
(en)
|
2015-07-07 |
2017-01-12 |
Janssen Vaccines & Prevention B.V. |
Vaccine against rsv
|
EA037295B1
(ru)
|
2015-08-20 |
2021-03-05 |
Янссен Вэксинс Энд Превеншн Б.В. |
Терапевтические вакцины против hpv18
|
EP3359132B1
(de)
|
2015-10-06 |
2023-08-16 |
Janssen Vaccines & Prevention B.V. |
Verfahren zur konservierung von biologischen produkten in kunststoffbehältern
|
WO2017139392A1
(en)
|
2016-02-08 |
2017-08-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Recombinant hiv-1 envelope proteins and their use
|
WO2017156272A1
(en)
|
2016-03-09 |
2017-09-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Recombinant hiv-1 envelope proteins and their use
|
AU2017248021B2
(en)
|
2016-04-05 |
2021-08-12 |
Janssen Vaccines & Prevention B.V. |
Stabilized soluble pre-fusion RSV F proteins
|
BR112018070323A2
(pt)
|
2016-04-05 |
2019-01-29 |
Janssen Vaccines & Prevention Bv |
vacina contra rsv
|
AU2017259259B2
(en)
|
2016-05-02 |
2020-11-19 |
Bavarian Nordic A/S |
Therapeutic HPV vaccine combinations
|
US20190134190A1
(en)
|
2016-05-04 |
2019-05-09 |
Transgene Sa |
Combination therapy with cpg tlr9 ligand
|
RU2758238C2
(ru)
|
2016-05-12 |
2021-10-26 |
Янссен Вэксинс Энд Превеншн Б.В. |
Эффективный и сбалансированный двунаправленный промотор
|
WO2017207480A1
(en)
|
2016-05-30 |
2017-12-07 |
Janssen Vaccines & Prevention B.V. |
Stabilized pre-fusion rsv f proteins
|
US11001858B2
(en)
|
2016-06-20 |
2021-05-11 |
Janssen Vaccines & Prevention B.V. |
Potent and balanced bidirectional promoter
|
WO2018011196A1
(en)
|
2016-07-14 |
2018-01-18 |
Janssen Vaccines & Prevention B.V. |
Hpv vaccines
|
CA3038968A1
(en)
|
2016-09-30 |
2018-04-05 |
Genvec, Inc. |
Adenovectors for delivery of therapeutic genetic material into t cells
|
US11602559B2
(en)
|
2016-10-03 |
2023-03-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
HIV-1 Env fusion peptide immunogens and their use
|
EP3522920A2
(de)
|
2016-10-10 |
2019-08-14 |
Transgene SA |
Immuntherapeutisches produkt und mdsc-modulator-kombinationstherapie
|
EP3532095A1
(de)
|
2016-10-25 |
2019-09-04 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Präfusionscoronavirus-spike-proteine und deren verwendung
|
CN110418650A
(zh)
|
2016-11-16 |
2019-11-05 |
免疫治疗有限公司 |
用于治疗过敏的核酸
|
MX2019006349A
(es)
|
2016-12-16 |
2019-08-22 |
Inst Res Biomedicine |
Proteinas recombinantes rsv f de prefusion nuevas y usos de las mismas.
|
CN110234658B
(zh)
|
2017-01-31 |
2024-03-12 |
辉瑞大药厂 |
脑膜炎奈瑟菌组合物及其使用方法
|
KR102111244B1
(ko)
|
2017-02-09 |
2020-05-15 |
얀센 백신스 앤드 프리벤션 비.브이. |
이종 유전자의 발현을 위한 강력한 짧은 프로모터
|
US11235056B2
(en)
|
2017-03-24 |
2022-02-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Glycan-masked engineered outer domains of HIV-1 gp120 and their use
|
US11203629B2
(en)
|
2017-04-22 |
2021-12-21 |
Immunomic Therapeutics, Inc. |
LAMP constructs
|
AU2018263923A1
(en)
|
2017-05-02 |
2019-10-31 |
Immunomic Therapeutics, Inc. |
LAMP (lysosomal associated membrane protein) constructs comprising cancer antigens
|
EP3624844A1
(de)
|
2017-05-17 |
2020-03-25 |
Janssen Vaccines & Prevention B.V. |
Verfahren und zusammensetzungen zur induzierung schützender immunität gegen rsv-infektionen
|
EP3681533A1
(de)
|
2017-09-15 |
2020-07-22 |
Janssen Vaccines & Prevention B.V. |
Verfahren zur sicheren induktion der immunität gegen rsv
|
JP7502991B2
(ja)
|
2017-10-16 |
2024-06-19 |
ボイジャー セラピューティクス インコーポレイテッド |
筋萎縮性側索硬化症(als)の治療
|
US11136356B2
(en)
|
2017-10-16 |
2021-10-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Recombinant HIV-1 envelope proteins and their use
|
US20200237799A1
(en)
|
2017-10-16 |
2020-07-30 |
Voyager Therapeutics, Inc. |
Treatment of amyotrophic lateral sclerosis (als)
|
SG11202003398SA
(en)
|
2017-10-31 |
2020-05-28 |
Janssen Vaccines & Prevention Bv |
Adenovirus vectors and uses thereof
|
SG11202003290RA
(en)
|
2017-10-31 |
2020-05-28 |
Janssen Vaccines & Prevention Bv |
Adenovirus and uses thereof
|
US11142551B2
(en)
|
2017-10-31 |
2021-10-12 |
Janssen Vaccines & Prevention B.V. |
Adenovirus and uses thereof
|
WO2019086450A1
(en)
|
2017-10-31 |
2019-05-09 |
Janssen Vaccines & Prevention B.V. |
Adenovirus and uses thereof
|
SG11202006399VA
(en)
|
2018-01-23 |
2020-08-28 |
Janssen Vaccines & Prevention Bv |
Influenza virus vaccines and uses thereof
|
AU2019231652A1
(en)
|
2018-03-06 |
2020-10-01 |
Precigen, Inc. |
Hepatitis B vaccines and uses of the same
|
WO2019222281A1
(en)
|
2018-05-15 |
2019-11-21 |
Immunomic Therapeutics, Inc |
Improved lamp constructs comprising allergens
|
WO2020010035A1
(en)
|
2018-07-02 |
2020-01-09 |
Voyager Therapeutics, Inc. |
Cannula system
|
JP2021529513A
(ja)
|
2018-07-02 |
2021-11-04 |
ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics,Inc. |
筋萎縮性側索硬化症および脊髄に関連する障害の治療
|
AU2019368218A1
(en)
|
2018-10-22 |
2021-05-27 |
New York University |
Recombinant GP120 protein with V1-loop deletion
|
TW202043256A
(zh)
|
2019-01-10 |
2020-12-01 |
美商健生生物科技公司 |
前列腺新抗原及其用途
|
MX2021012991A
(es)
|
2019-04-25 |
2021-12-10 |
Janssen Vaccines & Prevention Bv |
Antigenos de gripe recombinantes.
|
US20220273787A1
(en)
|
2019-05-15 |
2022-09-01 |
Janssen Vaccines & Prevention B.V. |
Co-administration of seasonal influenza vaccine and an adenovirus based respiratory syncytial virus vaccine
|
CA3140234A1
(en)
|
2019-05-15 |
2020-11-19 |
Janssen Vaccines & Prevention B.V. |
Prophylactic treatment of respiratory syncytial virus infection with an adenovirus based vaccine
|
CN114430742A
(zh)
|
2019-09-05 |
2022-05-03 |
扬森疫苗与预防公司 |
流感病毒疫苗及其用途
|
IL291852A
(en)
|
2019-10-03 |
2022-06-01 |
Janssen Vaccines & Prevention Bv |
Adenovirus vectors and their use
|
AU2020361533A1
(en)
|
2019-10-08 |
2022-04-28 |
Trustees Of Boston College |
Proteins containing multiple, different unnatural amino acids and methods of making and using such proteins
|
CA3153850A1
(en)
|
2019-10-18 |
2021-04-22 |
Teri Heiland |
Improved lamp constructs comprising cancer antigens
|
AU2020385683A1
(en)
|
2019-11-18 |
2022-06-30 |
Janssen Biotech, Inc. |
Vaccines based on mutant CALR and JAK2 and their uses
|
EP4103229A1
(de)
|
2020-02-11 |
2022-12-21 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Sars-cov-2-impfstoff
|
TW202144389A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在多發性骨髓瘤中表現之新抗原及其用途
|
TW202144388A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在卵巢癌中表現之新抗原及其用途
|
CA3170369A1
(en)
|
2020-03-05 |
2022-04-14 |
Michal Shahar |
Methods and compositions for treating cancer with immune cells
|
US11213482B1
(en)
|
2020-03-05 |
2022-01-04 |
University of Pittsburgh—Of the Commonwealth System of Higher Educat |
SARS-CoV-2 subunit vaccine and microneedle array delivery system
|
US11773391B2
(en)
|
2020-04-01 |
2023-10-03 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Therapeutic and diagnostic target for SARS-CoV-2 and COVID-19
|
JP2023521194A
(ja)
|
2020-04-13 |
2023-05-23 |
ヤンセン バイオテツク,インコーポレーテツド |
Psma及びsteap1ワクチン並びにそれらの使用
|
EP4142785A2
(de)
|
2020-04-29 |
2023-03-08 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Rekombinante menschliche metapneumovirus f proteine und deren verwendung
|
WO2021247995A2
(en)
|
2020-06-04 |
2021-12-09 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating neuropathic pain
|
US20230024133A1
(en)
|
2020-07-06 |
2023-01-26 |
Janssen Biotech, Inc. |
Prostate Neoantigens And Their Uses
|
EP4175664A2
(de)
|
2020-07-06 |
2023-05-10 |
Janssen Biotech, Inc. |
Prostata-neoantigene und ihre verwendungen
|
US20230035403A1
(en)
|
2020-07-06 |
2023-02-02 |
Janssen Biotech, Inc. |
Method For Determining Responsiveness To Prostate Cancer Treatment
|
EP4178605A1
(de)
|
2020-07-13 |
2023-05-17 |
Transgene |
Behandlung von immundepression
|
WO2022035860A2
(en)
|
2020-08-10 |
2022-02-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Replication-competent adenovirus type 4-hiv env vaccines and their use
|
WO2022232648A1
(en)
|
2021-04-29 |
2022-11-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Prefusion-stabilized lassa virus glycoprotein complex and its use
|
IL308018A
(en)
|
2021-04-30 |
2023-12-01 |
Kalivir Immunotherapeutics Inc |
Oncolytic viruses for different MHC expression
|
EP4380613A1
(de)
|
2021-08-03 |
2024-06-12 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Hiv-1 impfung und samt-247 microbizid zur vorbeugung von hiv-1 infektion
|
WO2023069987A1
(en)
|
2021-10-20 |
2023-04-27 |
University Of Rochester |
Rejuvenation treatment of age-related white matter loss cross reference to related application
|
WO2023081633A1
(en)
|
2021-11-02 |
2023-05-11 |
University Of Rochester |
Tcf7l2 mediated remyelination in the brain
|
WO2023091696A1
(en)
|
2021-11-19 |
2023-05-25 |
Christiana Care Gene Editing Institute, Inc. |
Adenovirus delivery system for cancer treatment
|
WO2023192835A1
(en)
|
2022-03-27 |
2023-10-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Base-covered hiv-1 envelope ectodomains and their use
|
WO2023196898A1
(en)
|
2022-04-07 |
2023-10-12 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Beta globin mimetic peptides and their use
|
WO2023201201A1
(en)
|
2022-04-10 |
2023-10-19 |
Immunomic Therapeutics, Inc. |
Bicistronic lamp constructs comprising immune response enhancing genes and methods of use thereof
|
WO2023213764A1
(en)
|
2022-05-02 |
2023-11-09 |
Transgene |
Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
|
EP4338727A1
(de)
|
2022-09-14 |
2024-03-20 |
Roquette Freres |
Adenovirus-formulierungen
|
WO2024091824A1
(en)
|
2022-10-26 |
2024-05-02 |
Ada Forsyth Institute, Inc. |
Differentiation and reprogramming of chondrocyte
|